Literature DB >> 3707811

Comparison of pharmacokinetic profiles of single and multiple doses of a slow release Oros oxprenolol delivery system in young normotensive and elderly hypertensive subjects.

I D Bradbrook, M Babiker, P Crome, H C Gillies, P J Morrison, H J Rogers, P Shotton.   

Abstract

Oxprenolol in an Oros 8/130 sustained release osmotic pump system (equivalent to 120 mg oxprenolol hydrochloride in a conventional formulation and releasing 8 mg h-1) was given to eight normal young subjects (mean age 23 years) and eight elderly hypertensive patients (mean age 77 years). The plasma concentration-time profiles of oxprenolol were determined over 32 h using gas liquid chromatography after the initial dose and following seven doses. The elderly patients had a significantly higher AUC and maximum plasma oxprenolol concentration following both the first and final doses studied. It is unlikely that this difference is due to a prolonged absorption phase in the elderly patients. Reduced drug clearance seems the most probable explanation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3707811      PMCID: PMC1400951          DOI: 10.1111/j.1365-2125.1986.tb05209.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  Pharmacokinetics of oxprenolol in normal subjects.

Authors:  W D Mason; N Winer
Journal:  Clin Pharmacol Ther       Date:  1976-10       Impact factor: 6.875

2.  Effects of inflammatory disease on plasma oxprenolol concentrations.

Authors:  M J Kendall; C P Quarterman; H Bishop; R E Schneider
Journal:  Br Med J       Date:  1979-08-25

3.  Effects of age and cigarette smoking on propranolol disposition.

Authors:  R E Vestal; A J Wood; R A Branch; D G Shand; G R Wilkinson
Journal:  Clin Pharmacol Ther       Date:  1979-07       Impact factor: 6.875

4.  Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection.

Authors:  M S Lennard; J H Silas; A J Smith; G T Tucker
Journal:  J Chromatogr       Date:  1977-03-11

5.  The effect of ageing on the hepatic clearance of propranolol.

Authors:  C M Castleden; C F George
Journal:  Br J Clin Pharmacol       Date:  1979-01       Impact factor: 4.335

6.  Protein binding of atenolol and propranolol to human serum albumin and in human plasma [proceedings].

Authors:  H E Barber; G M Hawksworth; N R Kitteringham; J Petersen; J C Petrie; J M Swann
Journal:  Br J Clin Pharmacol       Date:  1978-11       Impact factor: 4.335

7.  Effect of age on plasma propranolol levels.

Authors:  R E Schneider; H Bishop; R A Yates; C P Quarterman; M J Kendall
Journal:  Br J Clin Pharmacol       Date:  1980-08       Impact factor: 4.335

8.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

Authors:  D A Evans; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1980-04       Impact factor: 6.318

9.  A comparison of the pharmacokinetics of atenolol, metoprolol, oxprenolol and propranolol in elderly hypertensive and young healthy subjects.

Authors:  J W Rigby; A K Scott; G M Hawksworth; J C Petrie
Journal:  Br J Clin Pharmacol       Date:  1985-10       Impact factor: 4.335

10.  Predisposing factors in adverse reactions to drugs.

Authors:  N Hurwitz
Journal:  Br Med J       Date:  1969-03-01
View more
  2 in total

Review 1.  Novel drug delivery systems. An overview of their impact on clinical pharmacokinetic studies.

Authors:  P S Banerjee; J R Robinson
Journal:  Clin Pharmacokinet       Date:  1991-01       Impact factor: 6.447

Review 2.  Clinical pharmacokinetic considerations in the elderly. An update.

Authors:  S Dawling; P Crome
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.